Electrocore SEC Filings

ECOR NASDAQ

Welcome to our dedicated page for Electrocore SEC filings (Ticker: ECOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Untangling electroCore’s SEC paperwork can feel like neuromodulation without anesthesia—hundreds of pages of FDA jargon, patent claims, and cash-burn math buried in footnotes. If you have ever searched for “electroCore SEC filings explained simply” or wondered why a single 8-K could move the stock after a new migraine clearance, you are not alone.

Stock Titan turns that headache into clarity. Our AI-powered summaries translate every electroCore annual report 10-K simplified, each quarterly earnings report 10-Q filing, and all electroCore 8-K material events explained into plain English. Need real-time alerts on electroCore Form 4 insider transactions? We stream them the moment they hit EDGAR—so monitoring electroCore insider trading Form 4 transactions or tracking electroCore executive stock transactions Form 4 becomes effortless. Interactive dashboards pair key metrics—nVNS revenue, R&D outlays, and liquidity runway—with expert context, letting you focus on decisions, not document mining.

Dive deeper when questions arise: How did gammaCore sales trend this quarter? Our electroCore earnings report filing analysis highlights device unit growth. Curious about board pay? The electroCore proxy statement executive compensation section is pre-tagged and summarized. Want a quick refresher before earnings? Understanding electroCore SEC documents with AI surfaces the exact risk-factor changes since last year. From electroCore quarterly earnings report 10-Q filing insights to electroCore Form 4 insider transactions real-time, every disclosure is at your fingertips—updated continuously, explained clearly, and ready to guide your next move.

07/09/2025 04:31 PM

Filing

[SCHEDULE 13G/A] electroCore, Inc. SEC Filing

Rhea-AI Summary

Sensei Biotherapeutics, Inc. (SNSE) announced, via an Item 3.01 Form 8-K, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Nasdaq Listing Qualifications Staff confirmed that SNSE’s common stock maintained a closing bid of at least $1.00 for ten consecutive business days (17 June – 1 July 2025). As a result, the prior deficiency notice has been closed and the threat of delisting has been removed.

This resolution eliminates near-term listing risk, restores eligibility for index inclusion and institutional ownership mandates tied to national exchange status, and reduces investor concern over potential liquidity constraints. However, compliance depends on SNSE’s ability to keep its share price above the threshold; any sustained drop below $1.00 could trigger a new notice. The filing contains no new operational or financial data and does not alter the company’s underlying fundamentals.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Electrocore (ECOR)?

The current stock price of Electrocore (ECOR) is $6.95 as of July 16, 2025.

What is the market cap of Electrocore (ECOR)?

The market cap of Electrocore (ECOR) is approximately 52.7M.

What is the primary focus of electroCore, Inc.?

electroCore, Inc. focuses on developing non-invasive vagus nerve stimulation therapies for neurological disorders, pain management, and general wellness. Their technology is used in both medical and consumer applications.

How does electroCore generate revenue?

The company generates revenue through direct sales of FDA-cleared medical devices, wholesale distribution, and strategic partnerships that leverage its cutting-edge bioelectronic technology platform.

What conditions are targeted by electroCore's therapies?

Their therapies primarily address neurological conditions such as migraines, cluster headaches, and epilepsy, while also exploring applications in psychiatric and gastrointestinal disorders, as well as wellness and human performance enhancement.

How is electroCore positioned within the neuromodulation market?

electroCore is recognized as a commercial-stage bioelectronic medicine company that differentiates itself through clinically validated, non-invasive solutions. Its global presence and diverse product portfolio support its competitive market position.

What is TAC-STIM and who benefits from its use?

TAC-STIM is a portable, non-invasive vagus nerve stimulator designed to enhance focus, energy, and cognitive performance. It is utilized in high-pressure environments, including military training, and is part of the company’s broader wellness offerings.

What sets electroCore's technology apart from competitors?

The company’s focus on precision, safety, and clinical validation sets it apart. Its products combine state-of-the-art engineering with strong research backing, ensuring effective non-invasive treatments without the use of pharmaceuticals.